机构：[1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China[2]The George Institute for Global Health, University of New South Wales, Sydney, Australia[3]School of Statistics, University of Minnesota at Twin Cities, Minneapolis, Minnesota, USA[4]Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing, China神经科系统神经外科首都医科大学宣武医院[5]Department of Neurology and Psychiatry, Beijing Shijitan Hospital, Capital Medical University, Beijing, China[6]Department of Science and Technology, West China Hospital of Sichuan University, Chengdu, Sichuan, China四川大学华西医院[7]Department of Emergency, Xuanwu Hospital of Capital Medical University, Beijing, China内科系统急诊科首都医科大学宣武医院[8]Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China神经科系统神经内科首都医科大学宣武医院[9]The General Office of Stroke Prevention Project Committee, National Health Commission of the People’s Republic of China, Beijing, China
Background and rationaleCerebral venous thrombosis (CVT) is a rare cerebrovascular disorder that mainly affects young and middle-aged adults. Epidemiological data on the incidence, risk factors, diagnosis, treatment, and prognosis of CVT are lacking in China. In addition, there is a lack of evidence from large, multicenter, real-world studies on the efficacy and safety of endovascular.AimTo understand the incidence, diagnosis and treatment status of CVT in China and to estimate the effectiveness and safety of endovascular treatment in the real-world.MethodsA multicenter, retrospective observational cohort study will be conducted on CVT patient records from 104 hospitals, between January 1, 2018 and June 30, 2022, identified using a 2-stage cluster sampling design based on per capita gross domestic product. Each enrolled participant is required to complete a further follow-up, which includes the current situation and the assessment at 3 and 12 months after discharge.Study outcomesThe outcomes of this study will include the current status of the incidence, pathogenesis, etiology, clinical symptoms, diagnosis, and treatment of CVT in China, as well as the effectiveness and safety of endovascular treatment in the real-world.DiscussionResults from this study will provide evidence on the incidence, specific risk factors, symptomatic and imaging features, and clinical outcomes of CVT in China as well as indicate whether endovascular treatment is superior to medical management alone for patients with acute CVT in the real-world.Trial registrationhttp://www.clinicaltrials.gov.IdentifierNCT05448248 This is a protocal about our study. This protocal introduces the design, method and content of our research.
基金：
Beijing Science and Technology Planning
Project, Grant/Award Number:
Z181100001918026; Talent Construction
Fund of Beijing Institute of Brain Disorders,
Grant/Award Number:
PXM2020_014226_000004; National Natural
Science Foundation of China, Grant/Award
Number: 82027802
第一作者机构：[1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China
通讯作者：
通讯机构：[1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing, China[4]Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing, China[*1]Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China ,Department of Neurosurgery, Xuanwu Hospital of Capital Medical University, Beijing 100053, China.
推荐引用方式(GB/T 7714)：
Bian Hetao,Wang Xia,Liu Lan,et al.Multicenter registry study of cerebral venous thrombosis in china (RETAIN-CH): Rationale and design[J].BRAIN AND BEHAVIOR.2024,14(4):doi:10.1002/brb3.3353.
APA：
Bian, Hetao,Wang, Xia,Liu, Lan,Yan, Feng,Lu, Shan...&Ji, Xunming.(2024).Multicenter registry study of cerebral venous thrombosis in china (RETAIN-CH): Rationale and design.BRAIN AND BEHAVIOR,14,(4)
MLA：
Bian, Hetao,et al."Multicenter registry study of cerebral venous thrombosis in china (RETAIN-CH): Rationale and design".BRAIN AND BEHAVIOR 14..4(2024)
